Next 10 |
home / stock / sprb / sprb articles
NEW YORK, March 23, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce"?...
Spruce Biosciences Inc (NASDAQ:SPRB) shares plummeted on Thursday after the company released topline results from its CAHmelia-203 Phase 2b st...
U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling more than 100 points on Thursday. The Dow traded down 0.35% to...
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 100 points on Thursday. The Dow traded down 0.30% to 38...
U.S. stocks traded higher this morning, following the release of PPI data. Following the market opening Thursday, the Dow traded up 0.11% to 39,084...
Wednesday, Spruce Biosciences Inc (NASDAQ:SPRB) released topline results from its CAHmelia-203 Phase 2b study of tildacerfont in adult cl...
Shares of Robinhood Markets, Inc. (NASDAQ: HOOD) rose sharply in today’s pre-market trading after the company reported February trading metr...
Javier Szwarcberg, Chief Executive Officer at Spruce Biosciences (NASDAQ:SPRB), reported a large acquisition of company stock options on November 2...
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, whic...
News, Short Squeeze, Breakout and More Instantly...
Spruce Biosciences Inc. Company Name:
SPRB Stock Symbol:
NASDAQ Market:
Presentation to highlight baseline characteristics of Spruce’s CAHptain program evaluating tildacerfont in pediatric congenital adrenal hyperplasia (CAH) The company is also highlighting baseline characteristics from its CAHmelia program evaluating tildacerfont in adult CAH in a po...
Presentation to highlight baseline characteristics of Spruce’s CAHmelia program evaluating tildacerfont in adult congenital adrenal hyperplasia (CAH), as an illustration of outcomes of current pediatric CAH disease management Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-s...
Spruce Biosciences Inc (NASDAQ:SPRB) shares plummeted on Thursday after the company released topline results from its CAHmelia-203 Phase 2b st...